We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Merge and demerge

22 March 2004 By Robert Cyran

The Swiss drugs company may spin off its huge generics business if it buys Aventis, according to a report. The split would create value, even if it poses some difficult questions over which drugs belong where.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)